S&P 500   3,784.35 (+2.88%)
DOW   30,268.12 (+2.64%)
QQQ   281.15 (+2.79%)
AAPL   145.42 (+2.08%)
MSFT   248.04 (+3.03%)
META   140.38 (+1.28%)
GOOGL   101.42 (+2.82%)
AMZN   120.95 (+4.38%)
TSLA   248.10 (+2.35%)
NVDA   130.74 (+4.49%)
NIO   16.65 (+7.49%)
BABA   84.03 (+4.45%)
AMD   67.88 (+2.68%)
T   16.00 (+0.63%)
MU   54.09 (+4.58%)
CGC   3.13 (+7.56%)
F   12.28 (+7.06%)
GE   67.45 (+6.05%)
DIS   100.80 (+3.78%)
AMC   7.99 (+16.13%)
PYPL   92.49 (+6.09%)
PFE   44.26 (+0.27%)
NFLX   238.01 (-0.43%)
S&P 500   3,784.35 (+2.88%)
DOW   30,268.12 (+2.64%)
QQQ   281.15 (+2.79%)
AAPL   145.42 (+2.08%)
MSFT   248.04 (+3.03%)
META   140.38 (+1.28%)
GOOGL   101.42 (+2.82%)
AMZN   120.95 (+4.38%)
TSLA   248.10 (+2.35%)
NVDA   130.74 (+4.49%)
NIO   16.65 (+7.49%)
BABA   84.03 (+4.45%)
AMD   67.88 (+2.68%)
T   16.00 (+0.63%)
MU   54.09 (+4.58%)
CGC   3.13 (+7.56%)
F   12.28 (+7.06%)
GE   67.45 (+6.05%)
DIS   100.80 (+3.78%)
AMC   7.99 (+16.13%)
PYPL   92.49 (+6.09%)
PFE   44.26 (+0.27%)
NFLX   238.01 (-0.43%)
S&P 500   3,784.35 (+2.88%)
DOW   30,268.12 (+2.64%)
QQQ   281.15 (+2.79%)
AAPL   145.42 (+2.08%)
MSFT   248.04 (+3.03%)
META   140.38 (+1.28%)
GOOGL   101.42 (+2.82%)
AMZN   120.95 (+4.38%)
TSLA   248.10 (+2.35%)
NVDA   130.74 (+4.49%)
NIO   16.65 (+7.49%)
BABA   84.03 (+4.45%)
AMD   67.88 (+2.68%)
T   16.00 (+0.63%)
MU   54.09 (+4.58%)
CGC   3.13 (+7.56%)
F   12.28 (+7.06%)
GE   67.45 (+6.05%)
DIS   100.80 (+3.78%)
AMC   7.99 (+16.13%)
PYPL   92.49 (+6.09%)
PFE   44.26 (+0.27%)
NFLX   238.01 (-0.43%)
S&P 500   3,784.35 (+2.88%)
DOW   30,268.12 (+2.64%)
QQQ   281.15 (+2.79%)
AAPL   145.42 (+2.08%)
MSFT   248.04 (+3.03%)
META   140.38 (+1.28%)
GOOGL   101.42 (+2.82%)
AMZN   120.95 (+4.38%)
TSLA   248.10 (+2.35%)
NVDA   130.74 (+4.49%)
NIO   16.65 (+7.49%)
BABA   84.03 (+4.45%)
AMD   67.88 (+2.68%)
T   16.00 (+0.63%)
MU   54.09 (+4.58%)
CGC   3.13 (+7.56%)
F   12.28 (+7.06%)
GE   67.45 (+6.05%)
DIS   100.80 (+3.78%)
AMC   7.99 (+16.13%)
PYPL   92.49 (+6.09%)
PFE   44.26 (+0.27%)
NFLX   238.01 (-0.43%)
NYSE:GLS

Gelesis - GLS Price Target & Analyst Ratings

$1.13
0.00 (0.00%)
(As of 10/4/2022 02:06 PM ET)
Add
Compare
Today's Range
$1.13
$1.17
50-Day Range
$1.03
$1.63
52-Week Range
$1.01
$12.23
Volume
354 shs
Average Volume
196,525 shs
Market Capitalization
$82.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.15

Gelesis Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$1.15
1.77% Upside
High Prediction$1.15
Average Prediction$1.15
Low Prediction$1.15
TypeCurrent
10/4/21 to 10/4/22
1 Month Ago
9/4/21 to 9/4/22
3 Months Ago
7/6/21 to 7/6/22
1 Year Ago
10/4/20 to 10/4/21
Consensus Rating
Hold
N/AN/AN/A
Strong Buy
0 Strong Buy rating(s)
N/A N/A N/A
Buy
0 Buy rating(s)
N/A N/A N/A
Hold
1 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$1.15N/AN/AN/A
Predicted Upside1.77% UpsideN/AN/AN/A
Get Gelesis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GLS and its competitors with MarketBeat's FREE daily newsletter.


GLS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gelesis Stock vs. The Competition

TypeGelesisMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldBuyHold
Predicted Upside1.77% Upside1,074.35% Upside31.91% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
No Votes
Underperform Votes
1
100.00%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.38%
Avg. Underperform Votes
394
31.62%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/20/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$1.15+2.68%
(Data available from 10/4/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GLS Price Target - Frequently Asked Questions

What is Gelesis's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Gelesis stock is Hold based on the current 1 hold rating for GLS. The average twelve-month price prediction for Gelesis is $1.15 with a high price target of $1.15 and a low price target of $1.15. Learn more on GLS's analyst rating history.

Do Wall Street analysts like Gelesis more than its competitors?

Analysts like Gelesis less than other Medical companies. The consensus rating for Gelesis is Hold while the average consensus rating for medical companies is Buy. Learn more on how GLS compares to other companies.

Do MarketBeat users like Gelesis more than its competitors?

MarketBeat users like Gelesis less than other Medical companies. 0.00% of MarketBeat users gave Gelesis an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does Gelesis's stock price have much upside?

According to analysts, Gelesis's stock has a predicted upside of 2.68% based on their 12-month price targets.

What analysts cover Gelesis?

Gelesis has been rated by Citigroup in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:GLS) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.